Influenza A Virus

Dosage for Influenza A Virus allergenic extract is highly individualized and must be determined by an allergy specialist (allergist or immunologist). There is no 'standard' dose due to the non-standardized nature of the product.

• Diagnostic Skin Prick Test: Typically, one drop of the extract (e.g., 1:10 or 1:20 w/v) is applied to the skin, followed by a prick or scratch. A positive control (histamine) and a negative control (saline) are used for comparison.
• Intradermal Testing: If the prick test is negative, a dose of 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) may be injected into the dermis.
• Immunotherapy: Dosing begins at a very low concentration (the 'build-up phase') and increases weekly or bi-weekly until a maintenance dose is reached. The maintenance dose is the highest dose the patient can tolerate without a significant local or systemic reaction.

Influenza A Virus allergenic extract can be used in children, but the procedure requires extreme caution. Pediatric dosing is generally similar to adult dosing in terms of the concentration used for skin testing, but the volume and number of tests performed in one session may be reduced to minimize discomfort and the risk of systemic reactions. Your pediatrician or pediatric allergist will determine the appropriate protocol based on the child's age, weight, and clinical history. It is generally not recommended for infants unless specifically indicated by a specialist.

Renal Impairment

No specific dosage adjustments are required for patients with kidney disease, as the systemic absorption of the extract is minimal. However, the patient's overall health and ability to tolerate a potential systemic reaction should be considered.

Hepatic Impairment

No dosage adjustments are necessary for patients with liver impairment. The metabolic pathway of protein degradation is not significantly affected by liver enzyme capacity in the context of allergenic testing.

Elderly Patients

Older adults may have reduced skin reactivity (delayed or smaller wheal response), which can lead to false-negative results. Additionally, elderly patients often have underlying cardiovascular conditions that increase the risk of complications if a systemic allergic reaction occurs. Healthcare providers may use lower starting doses for immunotherapy in this population.

Influenza A Virus allergenic extract is never self-administered by the patient. It is always administered by a healthcare professional in a clinical setting.

• Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
• Administration: For testing, the skin is pricked or injected. For immunotherapy, the extract is injected subcutaneously (under the skin) in the upper arm.
• Observation: Patients MUST remain in the medical office for at least 30 minutes after any injection or skin test to be monitored for signs of anaphylaxis.
• Storage: The extract must be kept refrigerated at 2°C to 8°C (36°F to 46°F). It should never be frozen, as this can denature the proteins and render the extract ineffective or dangerous.

In the context of immunotherapy, consistency is vital. If a maintenance or build-up dose is missed, your doctor may need to reduce the dose for the next injection, depending on how much time has passed. Missing multiple doses may require restarting the build-up phase from a lower concentration to ensure safety.

An 'overdose' in the context of allergenic extracts refers to the administration of too much antigen, leading to a severe systemic reaction.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, difficulty breathing, rapid pulse, and a sharp drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (adrenaline), followed by antihistamines, corticosteroids, and emergency transport to a hospital.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to alter the schedule of your immunotherapy without medical guidance.

Most patients undergoing testing or treatment with Influenza A Virus allergenic extract will experience localized reactions at the site of administration. These are generally not dangerous but can be uncomfortable.

• Local Wheal and Flare: A raised, itchy bump (wheal) surrounded by redness (flare). This typically appears within 15-20 minutes and resolves within a few hours.
• Itching (Pruritus): Intense itching at the test site is a normal part of a positive reaction.
• Local Swelling: For immunotherapy injections, swelling up to the size of a half-dollar is common and may last for 24 to 48 hours.

• Large Local Reactions: Swelling that extends beyond the immediate injection site, sometimes involving the entire upper arm. This may require an adjustment in future dosing.
• Fatigue: Some patients feel significantly tired or 'run down' for several hours after receiving an allergenic extract.
• Headache: Mild to moderate headaches have been reported following immunotherapy sessions.

• Generalized Hives: Itchy bumps appearing on parts of the body far from the injection site.
• Nasal Congestion and Sneezing: A mild systemic 'hay fever' type response.
• Mild Wheezing: Shortness of breath that does not progress to full respiratory distress.

> Warning: Stop the procedure and call for emergency help immediately if you experience any of the following symptoms of anaphylaxis. These can occur within minutes of exposure.

• Difficulty Breathing or Swallowing: Feeling as though your throat is closing or your tongue is swelling.
• Wheezing or Chest Tightness: Audible whistling sounds when breathing or a feeling of intense pressure in the chest.
• Dizziness or Fainting: A sudden drop in blood pressure (hypotension) can cause lightheadedness or loss of consciousness.
• Rapid or Weak Pulse: Your heart may feel like it is racing or fluttering.
• Cyanosis: A bluish tint to the lips, face, or fingernails, indicating a lack of oxygen.
• Severe Abdominal Pain: Nausea, vomiting, or cramping can sometimes accompany systemic allergic reactions.

When used correctly for immunotherapy, the long-term goal is a beneficial change in the immune system. However, prolonged use of allergenic extracts carries a theoretical risk of developing new sensitivities, although this is rare. There is no evidence that long-term use of these extracts causes autoimmune diseases or chronic organ damage. The primary 'long-term' concern is the cumulative risk of a systemic reaction over years of treatment.

Allergenic extracts, including Influenza A Virus, carry a standard class-wide warning regarding the risk of severe systemic reactions.

Summary of FDA-Required Warning:

• This product can cause severe, life-threatening systemic reactions, including anaphylaxis.
• It should only be administered in a healthcare setting by personnel trained in the management of anaphylaxis.
• Patients with unstable asthma are at a higher risk for severe reactions.
• Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat a reaction.

Report any unusual symptoms, even those that seem minor, to your healthcare provider immediately.

Influenza A Virus allergenic extract is a potent biological product. It is intended only for use by physicians who are experienced in the administration of allergenic extracts and the treatment of allergic diseases. Because of the risk of systemic reactions, patients must be observed for at least 30 minutes following administration. If you have a history of severe asthma or previous severe reactions to viral antigens, you must inform your doctor, as these factors significantly increase your risk profile.

No specific individual black box warning exists for Influenza A Virus alone, but it falls under the mandatory class-wide black box warning for allergenic extracts. This warning emphasizes that these products can cause anaphylaxis and must be administered in a setting equipped with emergency resuscitative equipment, including oxygen, IV fluids, and epinephrine. The warning also notes that patients with severe or unstable asthma are at increased risk of fatal reactions.

• Anaphylaxis Risk: This is the primary concern. Reactions can range from mild hives to fatal shock. Your doctor will assess your current health status (e.g., if you have an active infection or a 'flare-up' of allergies) before each dose.
• Asthma Status: If your asthma is not well-controlled, you should not receive allergenic extracts. A peak flow meter or spirometry may be used to check your lung function before an injection.
• Cardiovascular Disease: Patients with heart disease may be less able to survive the physiological stress of a systemic reaction.
• Autoimmune Disorders: Use with caution in patients with active autoimmune diseases, as the stimulation of the immune system could theoretically worsen the condition.

While taking Influenza A Virus allergenic extract, your healthcare provider will monitor:

• The Injection Site: Checking for excessive swelling or redness.
• Vital Signs: Blood pressure and heart rate, especially if you feel unwell.
• Lung Function: Listening to your lungs for wheezing.
• Symptom Log: You may be asked to keep a diary of any 'late-phase' reactions that occur hours after you leave the clinic.

Generally, this extract does not affect your ability to drive. However, if you experience dizziness, fatigue, or a mild systemic reaction after your appointment, you should avoid driving until the symptoms have completely resolved.

There is no direct chemical interaction between alcohol and the Influenza A Virus extract. However, alcohol can cause vasodilation (widening of blood vessels), which may theoretically speed up the absorption of the allergen and increase the risk or severity of an allergic reaction. It is best to avoid alcohol for several hours before and after your treatment.

If you decide to stop immunotherapy, there are no 'withdrawal' symptoms. However, the benefits of the treatment (reduced sensitivity) will gradually diminish over time, and your original allergy symptoms may return. Always discuss the decision to stop treatment with your allergist.

> Important: Discuss all your medical conditions, especially respiratory and heart issues, with your healthcare provider before starting Influenza A Virus extract.

There are few absolute contraindications for drug combinations, but the following are critical:

• Beta-Blockers (e.g., Propranolol, Atenolol): These are often considered a contraindication for allergenic extracts. If you experience anaphylaxis, beta-blockers can block the life-saving effects of epinephrine (adrenaline), making the reaction much harder to treat and potentially fatal.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that patients on ACE inhibitors may be at a higher risk for more severe systemic reactions to allergenic extracts.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the body's ability to process certain stress hormones, potentially complicating the treatment of an allergic reaction.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can potentiate the effects of epinephrine, which may be problematic during emergency resuscitation.

• Antihistamines (e.g., Loratadine, Cetirizine): These medications suppress the skin's response to histamine. If you are taking them before a diagnostic skin test, the test may result in a 'false negative.' You must typically stop taking antihistamines for 3 to 7 days before skin testing.
• H2 Blockers (e.g., Famotidine): These can also mildly suppress skin test results and should be disclosed to your doctor.
• Systemic Corticosteroids: Long-term use of prednisone or other steroids can dampen the immune response and interfere with both diagnostic testing and the efficacy of immunotherapy.

There are no specific food-drug interactions for Influenza A Virus extract. However, if you have a known food allergy, a 'flare-up' of that allergy (e.g., eating something you are mildly allergic to) can prime your immune system and make you more likely to have a reaction to the viral extract injection.

• St. John's Wort: May have minor interactions with how the body handles stress responses, though clinical data is limited.
• High-dose Vitamin C: Some believe it has mild antihistamine properties, which could theoretically interfere with skin test accuracy.

Influenza A Virus extract primarily affects skin tests and specialized allergy blood tests (like RAST or ImmunoCAP). It does not typically interfere with standard blood chemistry, liver function tests, or urinalysis. However, it may cause a temporary increase in total IgE levels or specific IgG4 levels as part of the intended immune response.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure, depression, or allergies.

Influenza A Virus allergenic extract must NEVER be used in the following situations:

1. 1Severe, Unstable Asthma: If your asthma is not well-controlled (e.g., frequent nighttime symptoms or low peak flow), the risk of a fatal respiratory reaction to the extract is too high. The mechanism involves the potential for the extract to trigger a systemic release of mediators that cause immediate, severe bronchospasm.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The physiological stress of an allergic reaction or the administration of epinephrine could cause further heart damage.
3. 3Known Hypersensitivity to Extract Components: If you have had a previous life-threatening reaction to this specific extract or any of its inactive ingredients (such as phenol, which is used as a preservative).

These conditions require a careful risk-benefit analysis by your physician:

• Pregnancy: While not an absolute contraindication for continuing a maintenance dose, starting a new immunotherapy protocol during pregnancy is generally avoided due to the risk of fetal hypoxia (lack of oxygen) during a maternal anaphylactic reaction.
• Autoimmune Diseases: Conditions like Lupus (SLE) or Rheumatoid Arthritis may be exacerbated by immune system stimulation.
• Beta-Blocker Therapy: As mentioned, this makes treating a reaction difficult.
• Young Children: Children under 5 years old may have difficulty communicating the early symptoms of a systemic reaction.

Patients who are allergic to egg proteins should be tested with caution. Some influenza virus preparations are grown in embryonated chicken eggs, and although modern purification processes are excellent, trace amounts of egg protein (ovalbumin) may remain. If you have a severe egg allergy, your doctor will take extra precautions.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza A Virus extract.

Influenza A Virus allergenic extract is generally classified as Pregnancy Category C. This means that adequate and well-controlled studies in pregnant women have not been conducted. The primary concern is not that the extract itself is a teratogen (causes birth defects), but rather the risk of anaphylaxis. If a pregnant woman experiences a severe allergic reaction, her blood pressure may drop, leading to decreased blood flow to the placenta and fetal distress or death. Most allergists will not start new immunotherapy during pregnancy but may continue a maintenance dose if the patient is stable and the benefit outweighs the risk.

It is not known whether the components of Influenza A Virus allergenic extract are excreted in human milk. However, because the antigens are proteins and are administered in very small quantities, it is highly unlikely that they would be absorbed intact from the infant's gut. The risk to a nursing infant is considered very low. Breastfeeding mothers should still inform their doctors before receiving treatment.

Allergenic extracts are used in children, but the safety and efficacy depend on the child's ability to cooperate with the testing and the observation period. Children are at the same risk for anaphylaxis as adults. Special care is taken to ensure the child does not have an underlying respiratory infection at the time of the injection, as this can increase the risk of a reaction. There is no evidence that these extracts affect growth or development.

Elderly patients (over 65) may have a higher prevalence of cardiovascular and respiratory comorbidities. This population is more likely to be taking medications like beta-blockers or ACE inhibitors, which complicate the safety profile. Additionally, the skin's reactivity to allergens decreases with age, which can make diagnostic testing less reliable. Physicians often use a more conservative dosing schedule for older adults.

Renal impairment does not significantly change the way the body processes allergenic extracts. However, patients with chronic kidney disease (CKD) may have altered immune responses and may be more sensitive to the physiological stress of a systemic reaction. No specific GFR-based dose adjustments are published, but clinical monitoring is advised.

Liver disease does not affect the protein degradation pathways used to clear allergenic extracts. There are no specific adjustments for patients with Child-Pugh classification-based liver impairment. The primary concern in these patients would be overall health stability and the ability to tolerate emergency medications if needed.

> Important: Special populations require individualized medical assessment and a tailored approach to allergy testing and treatment.

Influenza A Virus allergenic extract acts as an exogenous antigen. In the diagnostic phase, it interacts with membrane-bound IgE on the surface of mast cells and basophils. This interaction causes the cross-linking of the high-affinity IgE receptor (FcεRI), triggering a signaling cascade that involves tyrosine kinases and an influx of calcium ions. This leads to the immediate release of pre-formed mediators (histamine, tryptase) and the synthesis of lipid mediators. In the therapeutic phase (immunotherapy), the mechanism shifts toward inducing immune tolerance. This involves the expansion of regulatory T-cells (Tregs) that produce IL-10 and TGF-β, which suppress Th2 responses and promote the production of IgG4 antibodies. These IgG4 antibodies act as 'decoy' receptors, binding the viral antigens before they can reach the IgE on mast cells.

• Onset of Action: For skin testing, the onset is rapid (15-20 minutes). For immunotherapy, the clinical benefit (reduction in symptoms) may take 6 to 12 months of consistent treatment.
• Duration of Effect: A positive skin test reaction usually fades within 2 to 4 hours. The effects of successful immunotherapy can last for several years after the treatment is discontinued.
• Tolerance: The goal of treatment is to induce immunological tolerance, which is the opposite of drug tolerance; it is a desired therapeutic outcome where the body no longer overreacts to the antigen.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local administration) |

| Protein Binding | N/A (Antigens are proteins themselves) |

| Half-life | Hours (Local) to Days (Systemic processing) |

| Tmax | 15-30 minutes (Local reaction) |

| Metabolism | Proteolysis (Proteins broken into peptides) |

| Excretion | Renal (as small peptides/amino acids) |

• Molecular Formula: Complex mixture of viral proteins (primarily HA and NA).
• Molecular Weight: Varies; Hemagglutinin is approximately 220 kDa (trimer).
• Solubility: Soluble in aqueous solutions (saline with phenol or glycerin).
• Structure: The extract contains the internal and surface proteins of the Influenza A Virus, typically prepared by aqueous extraction and filtration of the virus grown in a specific medium.

Influenza A Virus extract is classified as a Non-Standardized Allergenic Extract. It is grouped with other viral, bacterial, and fungal extracts used in immunology. Related medications include extracts for Influenza B, Mumps, and Candida albicans, which are also used for diagnostic or 'recall' antigen testing.